U.S., Nov. 21 -- ClinicalTrials.gov registry received information related to the study (NCT07951502) titled 'A Study of a New Induction and Dosing Schedule for Sublocade in Opioid Use Disorder' on Nov. 16.

Brief Summary: This study is looking at a new way to start Sublocade, a monthly injectable medicine already approved in Canada for opioid use disorder. Right now, most people start Sublocade with two doses of 300 mg, one month apart. This study is testing a different, more gradual approach: a smaller dose (50 mg) on Day 1, a second small dose (50 mg) on Day 7, and then the regular dose (300 mg) on Day 14.

The study team wants to find out whether this gradual approach helps people transitioning from methadone, or people who have used bup...